Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC (CHIPNOL)

Evaluation of the Impact of Combined Intraoperative Monitoring of Depth of Analgesia, Depth of Anesthesia and Continuous Hemodynamic Data on the Patients Recovery After Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy

The objective of our PILOT study is to evaluate the impact of a controlled (monitored) randomized anesthesia during cytoreductive surgery with HIPEC to oxaliplatin in order to treat adenocarcinomas of colorectal origin. The combination of NOL monitoring, BIS monitoring and continuous hemodynamic monitoring (FloTrac EV1000 system) can improve patient safety by reducing the length of hospital stay by decreasing total hypnotic doses and intraoperative opioids and side effects following anesthesia.

Study Overview

• Status: Terminated
• Conditions: Colorectal Neoplasms; Hyperthermia; Oxaliplatin
• Intervention / Treatment: Drug: Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively; Drug: Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices

Detailed Description

Title: Evaluation of the combined intraoperative monitoring of depth of analgesia (NOL), depth of anesthesia (BIS) and continuous hemodynamic data (Flotrac EV1000 system) on the patients' recovery after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). A pilot study.

Hypothesis: Investigators hypothesize that the intraoperative combination of new monitors, NOL index for depth of analgesia, BIS index for depth of anesthesia and Flotrac EV1000 system as continuous hemodynamic monitoring, to guide the delivery of opioids, hypnotics, fluids and inotropes, respectively, will improve the quality of recovery as well as the safety after anesthesia in patients undergoing HIPEC (Hyperthermic Intraperitoneal Chemotherapy) surgery.

Background: so far, only vital signs (mostly, blood pressure and heart rate) helped the anesthesiologist to administer hypnotics agents, analgesics, fluids and inotrope. Many devices have offered pain monitoring for anesthetized patients. The NOL index, a nociception monitor using a multiparametric approach, has shown an excellent sensitivity and specificity in detecting noxious stimuli under general anesthesia. More recently, it has been shown a strong inverse correlation between NOL index response to nociceptive stimulus and the increasing doses of opioid analgesia during surgery. Studies on post-operative outcomes when using intraoperative NOL monitoring to adapt nociception/anti-nociception balance during general anesthesia (GA) also reported in our center an improvement of the time to extubation and of the postoperative recovery criteria in PACU after colorectal surgery in the monitored group, leading to a quicker discharge from PACU (presented as an abstract at ASA 2018; manuscript in preparation). Recent studies also showed that avoiding too deep anesthesia by using the BIS index would improve patients' outcome in terms of morbi-mortality. It is also accepted that intra-venous fluid and inotropic/vasopressor drugs have an important effect on intra and postoperative patients' outcomes, in particular following major gastrointestinal surgery. The use of hemodynamic therapy management algorithms has been recommended in a report commissioned by the Centers for Medicare and Medicaid Services in the USA, and by the National Institute for Health and Care Excellence (NICE) in the UK as well as many groups working in ERAS protocols in Canada (and especially Montreal, McGill University) and worldwide.

Based on our recent systematic review (in preparation) and out of the 69 selected published articles, there is no study so far evaluating precisely the impact of anesthesia on postoperative outcomes, and no study combining the NOL, the BIS indexes and the Flotrac EV1000 system to evaluate the impact of a more precise anesthesia management on the postoperative outcomes after cytoreduction and HIPEC for peritoneal carcinomatosis of colorectal origin. Thus, the idea to propose the present study.

Specific Objectives: primary objective: to compare the time to reach the readiness for discharge from hospital and the total postoperative in-hospital length of stay between the Monitored group "M" (optimized, personalized and controlled anesthesia) versus the control group "C" (standard of care anesthesia). Secondary objectives: to evaluate the quality of recovery from anesthesia in the PACU and on the wards and all the adverse events every day and until patient's discharge from hospital. The emergence and extubation time of patients after anesthesia, time spent in PACU (Aldrete score), intra- and postoperative opioid requirements, pain scores (NRS) for several postoperative days, patients' postoperative recovery and satisfaction (the Quality of Recovery: QOR-15, 6min walking test, MOCA, etc.) will be also compared between the 2 groups. Finally, biological outcomes such as blood gas analysis, serum electrolytes, creatinine, DFG, hemoglobin, white blood cell and platelet counts, CRP, serum albumin, INR, PTT will be evaluated on a standard basis in both the groups.

Methods: 80 patients scheduled for HIPEC surgery with oxaliplatin for bowel adenocarcinoma surgery (without digestive resection) will be included. Randomisation will occur after the participant has provided informed consent and shortly before the surgical procedure is due to start. Patients in the Control group "C" will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100. In the Monitored group "M", the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume. Intraoperative epidural analgesia will be the same for all. Postoperative analgesia will be based on PCEA and hydromorphone for all. All anesthesia related side effects and quality of analgesia and rehabilitation will be evaluated daily and until patient's discharge from hospital.

Data Analysis: all data collected will be analyzed using an intent-to-treat approach. Summary statistics for each group, treatment effects, 95% confidence intervals, and p-values will be presented for primary and secondary outcomes, and process measures. Intraoperative data in the "M" and "C" groups will be compared using parametric (e.g. Student t-test) or non-parametric tests (e.g. Mann-Withney U test, Chi-squared test) depending on type of variables and distribution. General linear models will be used to carry out group comparisons on data on length of hospital stay. Potential pitfalls: analyses for secondary objectives may not be sufficiently powered but will nevertheless provide useful information for designing and conducting a future multicentric study. Bonferroni corrections will be used to protect against type I error.

Significance/Importance: Adding the NOL, the BIS and continuous hemodynamic monitoring will very likely reduce the total length of stay, and improve the postoperative speed and quality of recovery as well as will likely reduce the incidence of complications after cytoreduction + HIPEC procedures.

Study Design: Prospective, randomized controlled study.

Subject Population: Adult patients scheduled to undergo laparotomy for cytoreduction surgery + HIPEC for peritoneal carcinomatosis of colorectal origin and under general anesthesia with an active intraoperative epidural analgesia.

Sample Size: 80 patients will be evaluated in this study.

Study Duration: 2 year(s)

Study Center: Maisonneuve-Rosemont Hospital, Departments of Anesthesiology and Pain Medicine and Department of General Oncologic Surgery, CIUSSS de l'Est-de-l'Île-de-Montreal, Montreal, Quebec, Canada

Adverse Events: None expected.

Subvention/support: Department of Anesthesiology and Pain Medicine of HMR/CEMTL.

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montréal-Est, Quebec, Canada, H1T 2M4
      • Hopital Maisonneuve Rosemont, CIUSSS de l'est de l'Ile de Montréal

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ASA status I, II or III
• Patients older than 18 years
• HIPEC for bowel surgery with oxaliplatin + dextrose 5% for a duration of 30 min
• Duration and type of surgery requiring an epidural analgesia via an epidural catheter placed and tunnelled prior the general anesthesia induction and an arterial line placed after induction of general anesthesia.

Exclusion Criteria:

• Any allergy to one drug used in our anesthesia or HIPEC protocol
• Any contra-indication or patient's refusal for epidural placement
• Chronic arrhythmic cardiac conditions
• Chronic pain with use of opioids more than 3 times per week for 4 weeks
• Bowel occlusion
• Physical/mental incapacities
• Unexpected difficult airway requesting excessive, possibly painful airway manipulations.
• Epidural failure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Monitored group "M" (optimized controlled anesthesia); Patients in the Monitored group "M", the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume.	Drug: Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively; NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume; Other Names: Monitoring group
ACTIVE_COMPARATOR: Control group "C" (standard of care anesthesia); Patients in the Control group "C" will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100.	Drug: Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices; Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices; Other Names: Control group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The hospital length of stay in days	The length of hospital stay in group "M" versus group "C" will be evaluated with the readiness for discharge from hospital criteria. These criteria for hospital discharge will be precisely and daily evaluated based on the previous published literature from experts who reached a consensus (J.F. Fiore et al. Disease of the Colon and Rectum, volume 55: 4, 2012). After these criteria are achieved, discharge may take place.	Evaluated 24 hours postoperative and everyday until hospital discharge, up to 21 days
Tolerance of oral intake	The length of hospital stay in group "M" versus group "C" will be evaluated with the readiness for discharge from hospital criteria. These criteria for hospital discharge will be precisely and daily evaluated based on the previous published literature from experts who reached a consensus (J.F. Fiore et al. Disease of the Colon and Rectum, volume 55: 4, 2012) and this will include: - Tolerance of oral intake. After these criteria are achieved, discharge may take place.	Evaluated 24 hours postoperative and everyday until hospital discharge, up to 21 days
Recovery of lower gastrointestinal function	The length of hospital stay in group "M" versus group "C" will be evaluated with the readiness for discharge from hospital criteria. These criteria for hospital discharge will be precisely and daily evaluated based on the previous published literature from experts who reached a consensus (J.F. Fiore et al. Disease of the Colon and Rectum, volume 55: 4, 2012) and this will include: - Recovery of lower gastrointestinal function. After these criteria are achieved, discharge may take place.	Evaluated 24 hours postoperative and everyday until hospital discharge, up to 21 days
Adequate pain control with oral analgesia	The length of hospital stay in group "M" versus group "C" will be evaluated with the readiness for discharge from hospital criteria. These criteria for hospital discharge will be precisely and daily evaluated based on the previous published literature from experts who reached a consensus (J.F. Fiore et al. Disease of the Colon and Rectum, volume 55: 4, 2012) and this will include: - Adequate pain control with oral analgesia. After these criteria are achieved, discharge may take place.	Evaluated 24 hours postoperative and everyday until hospital discharge, up to 21 days
Ability to mobilize and self-care	The length of hospital stay in group "M" versus group "C" will be evaluated with the readiness for discharge from hospital criteria. These criteria for hospital discharge will be precisely and daily evaluated based on the previous published literature from experts who reached a consensus (J.F. Fiore et al. Disease of the Colon and Rectum, volume 55: 4, 2012) and this will include: - Ability to mobilize and self-care. After these criteria are achieved, discharge may take place.	Evaluated 24 hours postoperative and everyday until hospital discharge, up to 21 days
Clinical examination and laboratory tests show no evidence of complications or untreated medical problems	The length of hospital stay in group "M" versus group "C" will be evaluated with the readiness for discharge from hospital criteria. These criteria for hospital discharge will be precisely and daily evaluated based on the previous published literature from experts who reached a consensus (J.F. Fiore et al. Disease of the Colon and Rectum, volume 55: 4, 2012) and this will include: - Clinical examination and laboratory tests show no evidence of complications or untreated medical problems. After these criteria are achieved, discharge may take place.	Evaluated 24 hours postoperative and everyday until hospital discharge, up to 21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intraoperative anesthetic gas' consumption in ml/kg/h	Total consumption and absorption of desflurane in ml/kg/h during surgery and for each hour of surgery	Intraoperative
Intraoperative remifentanil consumption in mcg/kg/min	Total consumption of i.v. remifentanil during surgery and for each hour of surgery	Intraoperative
Intraoperative fluid's consumption in ml/h	Total of fluid perfused during surgery and for each hour of surgery	Intraoperative
Intraoperative number of hypotensive events	Total number of hypotensive events during surgery (defined as mean blood pressure below 60)	Intraoperative
Intraoperative phenylephrine consumption in mcg/kg/min	Total doses of intraoperative infused i.v. phenylephrine and doses per hour	Intraoperative
Intraoperative epidural consumption in 3 ml/h	Total doses of intraoperative Epidural infusion (lidocaine 2%+epinephrine) and doses per hour	Intraoperative
Time for awakening in seconds	Time for awakening (eyes opening) at the end of the surgery. Elapsed time in seconds between stopping the gas and opening the eyes of the patient	Intraoperative
Time for extubation in seconds	Time for extubation in seconds. Elapsed time in seconds between stopping the gas and patient's extubation	Intraoperative
Time for transfert to the PACU in seconds	Time for transfert to the PACU (Post Anesthesia Care Unit) in seconds, after extubatiuon	Intraoperative
First NRS pain score (0-10 scale) at times of awakening	NRS (Numeric Rating Scale) Pain Score evaluated at times of awakening, evaluation from 0 (no pain) to 10 (worst imaginable pain) scale	Intraoperative
First NRS pain score (0-10 scale) at arrival in PACU	First NRS Pain Score evaluated at arrival in PACU, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Postoperative, evaluated at arrival in PACU
NRS pain score (0-10 scale) at rest, in PACU	NRS Pain Score at rest, evaluated every 15 minutes until time for readiness for PACU discharge, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Postoperative, evaluated every 15 minutes until time for PACU discharge
NRS pain score (0-10 scale) with cough, in PACU	NRS Pain Score with cough, evaluated every 15 minutes until time for readiness for PACU discharge, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Postoperative, evaluated every 15 minutes until time for PACU discharge
NRS pain score (0-10 scale) on the Shoulder, in PACU	NRS Pain Score on the Shoulder, evaluated every 15 minutes until time for readiness for PACU discharge, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Postoperative, evaluated every 15 minutes until time for PACU discharge
Hydromorphone consumption (mg) in PACU	Total cumulative dose of titration of intravenous hydromorphone (mg), evaluated every 15 minutes until time for readiness for PACU discharge	Postoperative, evaluated every 15 minutes until time for PACU discharge
PONV score (0-3 scale) in PACU	PONV (PostOperative Nausea and Vomiting) score, evaluated every 15 minutes until time for readiness for PACU discharge, evaluation from 0 (no nausea) to 3 (nausea and vomiting)	Postoperative, evaluated every 15 minutes until time for PACU discharge
POSS score (1-4 scale) in PACU	POSS (Pasero Opioid-induced Sedation Scale) score evaluated every 15 minutes until time for readiness for PACU discharge, evaluation from 1 (awake and alert) to 5 (asleep deeply)	Postoperative, evaluated every 15 minutes until time for PACU discharge
Respiratory depression number in PACU	Respiratory depression number evaluated every 15 minutes until time for readiness for PACU discharge	Postoperative, evaluated every 15 minutes until time for PACU discharge
Blood pressure (mmHg) in PACU	Blood pressure (TAS/TAD/TAM) in mmHg evaluated every 15 minutes until time for readiness for PACU discharge	Postoperative, evaluated every 15 minutes until time for PACU discharge
Time for PACU discharge based on Aldrete scores (0-10 scale), in PACU	Time for readiness for PACU discharge based on Aldrete scores (0-10), Aldrete score must be ≥ 9 for PACU discharge	Postoperative, evaluated every 15 minutes until time for PACU discharge
NRS pain score (0-10 scale) at rest, evaluated everyday from 24 hours postoperative to hospital discharge	NRS Pain Score at rest, evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
NRS pain score (0-10 scale) with cough, evaluated everyday from 24 hours postoperative to hospital discharge	NRS Pain Score with cough, evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
NRS pain score (0-10 scale) on the Shoulder, evaluated everyday from 24 hours postoperative to hospital discharge	NRS Pain Score on the Shoulder, evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge, evaluation from 0 (no pain) to 10 (worst imaginable pain)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Hydromorphone consumption (mg), evaluated everyday from 24 hours postoperative to hospital discharge	Total cumulative dose of titration of intravenous hydromorphone (mg), evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Epidural consumption (mg), evaluated everyday from 24 hours postoperative to hospital discharge	Total cumulative dose of titration of epidural (mg), evaluated every day, from 24 hours postoperative until the cessation of the PCEA (Patient Controlled Epidural Analgesia)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
PONV score (0-3 scale), evaluated everyday from 24 hours postoperative to hospital discharge	PONV (PostOperative Nausea and Vomiting) score, evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge, evaluation from 0 (no nausea) to 3 (nausea and vomiting)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
POSS score (1-4 scale), evaluated everyday from 24 hours postoperative to hospital discharge	POSS (Pasero Opioid-induced Sedation Scale) score evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge, evaluation from 1 (awake and alert) to 5 (asleep deeply)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Respiratory depression number, evaluated everyday from 24 hours postoperative to hospital discharge	Respiratory depression number evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Blood pressure (mmHg), evaluated everyday from 24 hours postoperative to hospital discharge	Blood pressure (TAS/TAD/TAM) in mmHg evaluated every day, from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Heart rate (bpm), evaluated everyday from 24 hours postoperative to hospital discharge	Heart rate (HR) in bpm (beats per minute), evaluated every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Oxygen saturation (%), evaluated everyday from 24 hours postoperative to hospital discharge	Oxygen saturation (SPO2) in %, evaluated every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Respiratory rate (bpm), evaluated everyday from 24 hours postoperative to hospital discharge	Respiratory rate (RR) in bpm (breaths per minute), evaluated every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Temperature (°C), evaluated everyday from 24 hours postoperative to hospital discharge	Temperature (T°C), evaluated every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Overall patient's satisfaction (0-100%), evaluated everyday from 24 hours postoperative to hospital discharge	Overall patient's satisfaction, evaluated every day from 24 hours postoperative until time for readiness for hospital discharge, evaluation from 0 (unsatisfied) to 100% (fully satisfied)	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Quality of recovery (QoR-15), evaluated every day from 24 hours postoperative to hospital discharge	Patients' perceived quality of recovery (QoR-15). This questionnaire includes 15 questions that are divided into 2 parts, part A contains the first 10 questions that are scored between 0 (never) and 10 (constantly), and part B contains the last 5 questions scored between 0 (constantly) and 10 (never). Evaluation test every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
6-minutes walking score, evaluated every day from 24 hours postoperative to hospital discharge	6-minutes walking score. The object of this test is to walk as far as possible for 6 minutes in the hospital hallway. Six minutes is a long time to walk after this surgery type, so it's important to practise 6 Minute Walk every day on a flat hard surface. Evaluation test every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
MOCA scores, evaluated every day from 24 hours postoperative to hospital discharge	MOCA (Montreal Cognitive Assessment) scores test for Dementia, range from zero to 30, with a score of 26 and higher generally considered normal. In the initial study data establishing the MoCA, normal controls had an average score of 27.4, compared with 22.1 in people with mild cognitive impairment (MCI) and 16.2 in people with Alzheimer's disease. Evaluation test every day from 24 hours postoperative until time for readiness for hospital discharge	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Time for first walking/mobilization, evaluated every day from 24 hours postoperative to hospital discharge	The time for first walking/mobilization, consist to determine the precise moment when the patient is able to get up from his bed, and sit on a chair, with and without help	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Time for first flatus, evaluated every day from 24 hours postoperative to hospital discharge	Determine the time of first flatus which are a sign of recovery of lower GI function	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Time for return to food oral intake, evaluated every day from 24 hours postoperative to hospital	Patient is able to tolerate at least one solid meal without nausea, vomiting, bloating or worsening abdominal pain. Patient drinks liquids actively (ideally > 800-1000 ml/day) and do not require intravenous fluids infusion to maintain hydration	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Biological analysis, evaluated every day from 24 hours postoperative to hospital discharge	Biological analysis, intraoperative and daily during the 21 postoperative days: serum electrolytes (Na+ Cl- Ca2+ Ca total Phophore, glycemia) creatinine, DFG, CRP, hemoglobin, white blood cell and platelet counts, serum albumin, INR, PTT	Evaluated 24 hours postoperative, then everyday until hospital discharge, an average of 21 days
Rate of hospital readmission and mortality postoperative	Rate of hospital readmission and mortality postoperative up to 30 days following surgery	Postoperative evaluation, up to 30 days following surgery

Collaborators and Investigators

• Sponsor: Ciusss de L'Est de l'Île de Montréal

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 8, 2019
• Primary Completion (ACTUAL): November 30, 2020
• Study Completion (ACTUAL): November 30, 2020

Study Registration Dates

• First Submitted: July 16, 2019
• First Submitted That Met QC Criteria: September 21, 2019
• First Posted (ACTUAL): September 26, 2019

Study Record Updates

• Last Update Posted (ACTUAL): October 8, 2021
• Last Update Submitted That Met QC Criteria: September 30, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: Monitoring; HIPEC; Anesthesia; Oxaliplatin; Colorectal; Peritoneal; Carcinomatosis; Cytoreduction
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Wounds and Injuries; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Body Temperature Changes; Heat Stress Disorders; Colorectal Neoplasms; Hyperthermia; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics, General; Anesthetics; Analgesics, Opioid; Narcotics; Anesthetics, Inhalation; Remifentanil; Desflurane
• Other Study ID Numbers: 2019-1788

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No